Galderma wins FDA approval for Vectical™ Ointment for mild-to-moderate plaque psoriasis
Galderma wins FDA approval for Vectical Ointment for mild-to-moderate plaque psoriasis
Dermatology Nursing, July-August, 2009
Galderma Laboratories announced that the U.S. Food and Drug Administration approved Vectical[TM] (calcitriol) Ointment 3 mcg/g, a vitamin D3 product for the treatment of mild-to-moderate plaque psoriasis in adults.
Vectical Ointment is the only vitamin D3 ointment of its kind available in the United States. Vectical Ointment contains calcitriol, the naturally occurring, active form of vitamin D3, and is one of the only vitamin D3 products shown in clinical trials to be well-tolerated even when used on sensitive skin fold areas.
For more information on Vectical Ointment, visit www.Vectical.com; for more information on Galderma, lotion psoriasis visit www.gaidermaUSA.com
Leave a Comment